BRCA2 and breast carcinoma: However, a subgroup analysis showed an association between RRSO and risk-reduction in primary breast cancer in BRCA2 P/LP variant carriers (RR 0.63; 95% CI 0.41–0.97) but not for CBC (RR 0.35; 95% CI 0.07–1.74).